We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Five companies are throwing their support behind Sequenom’s efforts to have the U.S. Supreme Court reconsider the limits of patent eligibility. Read More
It took Pfizer and Allergan less than 48 hours to nix their plan to build one of the world’s largest drugmakers, placing the blame squarely on the U.S. Treasury Department. Read More
The largest drug merger of all time could be at risk of falling through after the U.S. Treasury Department late Monday issued a set of regulations that reduce the benefit of tax inversion deals. Read More
Pricing transparency is a key ingredient in bringing down prescription drug costs, according to a policy paper from the American College of Physicians. Read More
The FTC is suing Endo Pharmaceuticals and several other drugmakers over what it calls the illegal use of pay-for-delay settlements to block the market entry of generic forms of Opana ER and Lidoderm. Read More